Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cleo Diagnostics's Other Operating Expense for the
six
months ended in Dec. 2025 was A$0.23 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$2.01 Mil.
Cleo Diagnostics's quarterly Other Operating Expense
increased
from Dec. 2024 (A$0.21 Mil) to Jun. 2025 (A$1.78 Mil) but then
declined
from Jun. 2025 (A$1.78 Mil) to Dec. 2025 (A$0.23 Mil).
Cleo Diagnostics's annual Other Operating Expense
increased
from Jun. 2023 (A$0.63 Mil) to Jun. 2024 (A$3.20 Mil) and
increased
from Jun. 2024 (A$3.20 Mil) to Jun. 2025 (A$3.34 Mil).
Cleo Diagnostics Other Operating Expense Related Terms
Cleo Diagnostics Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Cleo Diagnostics's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$2.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of A$2.01 Mil mean?
Cleo Diagnostics (ASX:COV) has a Other Operating Expense of A$2.01 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Cleo Diagnostics and its competitors.
Is Cleo Diagnostics' Other Operating Expense too high?
Cleo Diagnostics' current Other Operating Expense is A$2.01 Mil. Overall, Cleo Diagnostics has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Cleo Diagnostics' Other Operating Expense compare to ABT and SYK?
Cleo Diagnostics' Other Operating Expense of A$2.01 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Medical Devices & Instruments company?
A good Other Operating Expense depends on the Medical Devices & Instruments industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Cleo Diagnostics and its competitors. Cleo Diagnostics's current Other Operating Expense is A$2.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleo Diagnostics stock overvalued right now?
Cleo Diagnostics (ASX:COV) has a current Other Operating Expense of A$2.01 Mil. The current Other Operating Expense is A$2.01 Mil. Cleo Diagnostics' overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Cleo Diagnostics (ASX:COV), the current Other Operating Expense is A$2.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which results to accurately differentiate patients with malignant ovarian cancer from those with benign gynecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.
6GF Score
Get the complete analysis for ASX:COV
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:COV has been successfully added to your 
